Medtech Talk

Gelfand and Levin Share Lessons from Ardian’s Rise and Fall…and Rise Again. Would They Do It Again?

05.06.2019 - By HealthegyPlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

Howard Levin and Mark Gelfand, the principals of Coridea, return to the podcast to detail the trials and tribulations of Ardian. Ardian is one of the bigger #medtech #startup stories over the past two decades. In 2011, Medtronic agreed to pay $800 million upfront for this company that pushed the once crazy idea of ablating renal nerves to lower hypertension. Ardian had raised $70 million from a syndicate of blue chip investors after being forged in the Foundry incubator. VCs proudly shared th...

More episodes from Medtech Talk